- Global Pharma News & Resources

Press Releases - 2021-06-03

Date Title Company
03-Jun-2021 INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ) Businesswire
03-Jun-2021 Clinical Trial Results of the BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent Commented in American Society of Hematology’s Medical Journal, Blood Businesswire
03-Jun-2021 Privo Technologies, Inc. to Present Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the Upcoming 2021 ASCO Annual Meeting Newswire
03-Jun-2021 Kansas Manufacturing Solutions and BioKansas Partner to Help Kansas Biomanufacturers Prosper Businesswire
03-Jun-2021 IGEA announces changes in its board and other corporate updates IGEA Pharma N.V.
03-Jun-2021 Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Businesswire
03-Jun-2021 LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial Businesswire
03-Jun-2021 LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial Businesswire
03-Jun-2021 Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Businesswire
03-Jun-2021 NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure Businesswire
03-Jun-2021 Global Oncology Innovation Continues Despite Pandemic; Global R&D Pipeline Reached 3,500 New Drugs in 2020, up 75% from 2015, Says New Report from the IQVIA Institute for Human Data Science Businesswire
03-Jun-2021 BioKansas Partners With BIO to Provide Equity, Inclusion, and Career Programming Businesswire
03-Jun-2021 Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference Businesswire
03-Jun-2021 Apyx Medical Corporation to Participate in the JMP Securities Life Sciences Conference Businesswire
03-Jun-2021 Stratasys Introduces All-in-One J5 MediJet Medical 3D Printer Businesswire
03-Jun-2021 Energous to Present at the LD Micro Invitational XI Businesswire
03-Jun-2021 Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China Businesswire
03-Jun-2021 Purdue Pharma L.P. to Begin Soliciting Votes for its Broadly Supported Chapter 11 Plan of Reorganization Businesswire
03-Jun-2021 AscellaHealth Launches Industry Newsletter, “Directions in Specialty Pharmacy”: Features Quality & Cost Containment Strategies for Medical and Pharmacy Benefit Businesswire
03-Jun-2021 US Study Finds Antibody Developed From Common Cold Reacts To Covid-19 Infection Efficiently DailyHeraldBusiness